Editorial Policies and Processes

All manuscripts received go through a perfectly defined editorial process.

The journal runs a policy to screen for plagiarism, manipulation of citations and falsification/fabrication of data.

Detailed peer review process of evaluation followed by the journal (phases, possible results): 

Details on the peer review process used by the journal (phases, possible outcomes)

Peer review

All manuscripts received go through the following editorial process phases.

  1. After receipt of the manuscript, the editor performs an initial evaluation to verify that it fits the aims of the journal and complies with all the requirements. He also monitors for plagiarism. During this process, the manuscript can be rejected, returned to the authors asking for further information or changes to be made or we move to the next step.
  2. Peer review. When the manuscript passes phase 1, it is sent to at least two independent reviewers who evaluate the manuscript’s scientific quality. This phase is double-blind, and neither the authors nor the reviewers know who the other party is. Nor does each reviewer know who the other is. Only the editor has all the information. During this phase, the reviewers can propose rejection, acceptance or making some changes to improve the manuscript’s scientific quality. He can also request further rounds of review. In case of discrepancies between reviewers on the rejection of the manuscript, the manuscript will be sent to a third reviewer. Finally, the editor sends the authors the necessary review reports and they generate a final version of their manuscript.
  3. The editor is the person responsible for the final decision on rejection or acceptance of the manuscript to publish. In the event of being accepted, it is sent for layout. Once the manuscript’s layout is complete, it is reviewed again by the editor and sent to the authors for approval.

Once the entire process is completed, it is published on the website in fully citable HTML format. When the publication date for the next number arrives, it is published in PDF format and forms part of the corresponding number.

Manuscripts submitted for publication will be reviewed by at least two reviewers external to the Editorial Board. See evaluation questionnaires

Publication Ethics and Publication Malpractice Statement

FARMACÉUTICOS COMUNITARIOS Journal Publication Ethics and Publication Malpractice Statement is based, in large part, on the guidelines and standards developed by the Committee on Publication Ethics (COPE). The relevant duties and expectations of authors, reviewers, and editors of the journal are set out below.

Policy for the review of articles drawn up by editors and members of the editorial board

The editors will not take decisions in the event of papers written by themselves, their relatives or work colleagues; nor when the content is related to products or services with whom the editors have any conflict of interest. In all cases the journal’s usual procedure will be followed, and peer review will be performed independently of the editor involved and his research groups.


Whoever carries out an evaluation must consider the work to be reviewed as a confidential document until its publication, both during and after the review process.

Under no circumstances should they disseminate or use the information, details, arguments or interpretations contained in the text under review for their own benefit or that of others, or to the detriment of third parties. Only in special cases may he/she seek the advice of other specialists in the field, a circumstance of which he/she must inform the management of the journal or book collection. 

Journal ethics policies

FARMACÉUTICOS COMUNITARIOS only agrees to publish studies that comply scrupulously with the Declaration of Helsinki ethics principles for research on humans that can be consulted at this link. The authors should make an express declaration and the lead author is responsible for the truth of the declaration. All manuscripts that do not comply with these ethics criteria will be rejected.

For edition, FARMACÉUTICOS COMUNITARIOS adopts the Spanish Agency of the Higher Council for Scientific Research periodic and single publications Good Practice Guide that can be consulted at this link.

Ethics responsibilities (conflict of interest, protection of human research subjects and animal research, informed consent)

Authors are required to make a conflict of interest and sources of finance declaration. In the event of commercial sponsorship, the aim of the study and content published is ensured. Those manuscripts that raise doubts over objectivity are rejected.

Texts with content that promotes social, racial, political, sexual, or religious discrimination will not be accepted for publication.

When experiments with humans or animals are reported, this requires a declaration that states that all procedures used are in accordance with ethics regulations.

Patients and participants in studies have the right to privacy, and this should not be breached without their informed consent. 

Papers drawn up with financial Support should be approved by the institution for them to be published.

The journal does not accept works previously published elsewhere. The authors are responsible for obtaining the correct permission to partially reproduce material (text, tables or figures) from other publications. Their sources will be cited.

If it is detected that the paper partially or fully plagiarises a work already published, it will be automatically rejected and its publication in FARMACÉUTICOS COMUNITARIOS prohibited.

The full document on ETHICS RESPONSIBILITIES can be downloaded here.

Copyright declaration

In compliance with the journal’s requirements, WE HEREBY DECLARE:

• That this is an original work.

• That it has not been partially or fully published elsewhere.

• That it is not in the process of evaluation in any other publication.

• That all the authors are responsible for the manuscript’s final version to whose preparation they contributed.

• That in the event of being accepted for its publication, we transfer all copyright to SEFAC. The latter hereby assumes all the exclusive rights to edit, publish or reproduce this in any format, and without whose permission none of the materials comprising this can be partially or fully published.

Procedures carried out with the publication of a new document, classified as erratum or retraction

The correction of the error or reason for the retraction of the paper is recorded always referring to the original. This new document has its own identification and continues the same indexing as the original paper. In the event of errata, the original document is kept and at the end of the text the correction is recorded referring to the document that published the erratum. In the event of retractions, the original document is replaced by a message that says that the document was withdrawn and reference to the retraction document is made.

Queries and claims

Please contact our editorial office (secretariatecnica@sefac.org) if you have any questions. For any inquiry or appeal related to the editorial process of your article or the final editorial decision, send an e-mail to the Editor-in-Chief at director.revista@sefac.org.es. The Editor-in-Chief will personally review all complaints and appeals, consulting, if necessary, other members of the editorial team. We will try to answer any appeals as quickly as possible.

The journal will use the necessary means to correct the literature and ensure the integrity of the published content. To do so, it shall use the appropriate means (corrections, expressions of concern, retractions) depending on the problem detected and its impact, as soon as possible after the identification of the problem.


Manual for authors

Journal Information